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Abstract
Background: In Huntington's disease (HD), age at neurological onset is inversely correlated with
the length of the CAG trinucleotide repeat mutation, but can be modified by genetic factors beyond
the  HD  gene. Association of a relatively infrequent 16 TAA allele of a trinucleotide repeat
polymorphism in the GRIK2 3'UTR with earlier than expected age at neurological onset has been
suggested to reflect linkage disequilibrium with a functional polymorphism in GRIK2 or an adjacent
gene.
Results:  We have tested this hypothesis by sequencing all GRIK2  exons, the exon-flanking
sequences and 3'UTR in several individuals who were crucial to demonstrating the modifier effect,
as they showed much earlier age at neurological onset than would be expected from the length of
their HD CAG mutation. Though ten known SNPs were detected, no sequence variants were
found in coding or adjacent sequence that could explain the modifier effect by linkage disequilibrium
with the 16 TAA allele. Haplotype analysis using microsatellites, known SNPs and new variants
discovered in the 3'UTR argues against a common ancestral origin for the 16 TAA repeat alleles in
these individuals.
Conclusion: These data suggest that the modifier effect is actually due to the TAA repeat itself,
possibly via a functional consequence on the GRIK2 mRNA.
Background
Huntington disease (HD [MIM 143100]) is a neurodegen-
erative disorder caused by an expanded CAG trinucleotide
repeat that lengthens a polyglutamine tract near the
amino terminus of the huntingtin protein [1]. The muta-
tion involves a "gain-of-function" that leads to the selec-
tive loss of vulnerable neurons, most notably medium
spiny neurons in the caudate nucleus, and results in char-
acteristic progressive writhing movements, in addition to
psychological changes and cognitive decline [2]. The age
at onset of HD is variable, though the motor disturbance
typically begins in mid-life, and is followed by an inexo-
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rable decline that ends in death after a course of 10–20
years. The length of the expanded CAG trinucleotide tract
is the primary determinant of disease onset, although the
mechanism whereby mutant huntingtin triggers the cas-
cade of HD pathogenesis that eventually produces these
symptoms is not yet clear [3,4]. Like several other poly-
glutamine neurodegenerative disorders, there is a strong
inverse correlation between the length of the poly-
glutamine tract and the age at neurologic onset, with the
longest mutations leading to juvenile HD. Indeed, the HD
CAG repeat length alone accounts for more than half of
the overall variance in age at neurologic onset. We and
others have showed that the remaining variation in age at
neurologic onset of HD is highly heritable and that other
genetic factors act to modify the pathogenic process [5-
16]. Identification and characterization of such modifiers
is of critical importance, since their capacity to alter patho-
genesis would make them potential targets for develop-
ment of therapeutics for this currently untreatable
disorder.
To date, one candidate genetic modifier of HD has been
confirmed in multiple independent studies. An associa-
tion between genetic variation at GRIK2  (GenBank:
mRNA NM_021956), encoding the GluR6 subunit of the
kainate receptor, and age at neurologic onset in HD was
first reported by Rubinsztein et al., based on 293 HD
patients from the United Kingdom [13]. A TAA repeat pol-
ymorphism (D6S1028; CHLC.ATA22H10) in the 3'
untranslated region (UTR) of GRIK2 accounted for 13% of
the residual variance in onset age after accounting for the
effect of the HD CAG mutation. The 16 repeat allele (des-
ignated '155' based on the PCR product length) was found
in those with younger than expected HD onset ages, lead-
ing to the suggestion that the TAA repeat was a neutral
polymorphism in linkage disequilibrium with a func-
tional variant in GRIK2, or in a nearby gene. The GRIK2
association was confirmed in 258 unrelated U.S. HD
patients, where the relatively rare 16 TAA allele was asso-
ciated with an approximate 5-year-younger age at onset
[11]. Subsequently, a modifier role for this locus has been
demonstrated in HD populations from France, India, and
Italy [6,7,12]. To address the issue of a functional variant
at or near the GRIK2 locus, we have tested whether a cod-
ing sequence variant explains the modifier effect, and sub-
sequently, we have used analysis of polymorphisms in the
GRIK2  region to implicate the TAA repeat itself as the
source of the genetic modification of onset age.
Results
Testing for a functional coding sequence variant in GRIK2
The GRIK2 TAA repeat displays at least 8 alleles, ranging
from 10 to 17 TAA units, though more than 90% of chro-
mosomes have 13, 14 or 15 repeats. The largest alleles, 16
and 17 TAAs, make up only 3.1% and 0.3% of chromo-
somes in our sample (n = 622), respectively. Our original
confirmation of the GRIK2 modifier effect employed 258
unrelated affected individuals of known onset available to
the Massachusetts HD Center Without Walls and did not
account for subsequently defined effects of the normal
HD CAG allele and interaction between the mutant and
wild-type CAGs [11]. We have now expanded this test
population to 311 individuals, genotyped for both the
HD CAG repeat and the GRIK2 TAA repeat. The variability
in onset age attributable to the HD CAG repeat, wild-type
HD CAG and interaction of the two [ln (age at onset) =
HD CAG repeat + normal CAG repeat + (HD CAG
repeat)*(normal CAG repeat)] is R2 = 0.743. When the
presence of a 16 TAA repeat allele is added to the model,
a statistically significant amount of the variability in onset
age is explained: R2 = 0.748, (16 allele genotypes, p  =
0.02). Those genotypes that include a 16 allele have a
mean age at onset approximately 4.5 years younger than
persons with only other GRIK2 alleles.
On the basis of these data, we selected three individuals
who possessed a 16 TAA allele and displayed much earlier
onset of HD than expected based upon their respective
CAG repeats. GUS17507, GUS3225 and GUS17508, had
CAG repeats of 45, 46 and 47 units, respectively, which
would typically be associated with onset between 50 and
58 years of age (Table 1). However, they displayed onset
of neurologic symptoms at 33, 28 and 29 years, respec-
tively. These three individuals contributed strongly to the
detection of the modifier effect above, since leaving them
out of the analysis dramatically altered the p value for the
effect (p  = 0.13). We also selected one individual,
GUS17843 with a rare 17 TAA allele, a HD CAG repeat of
46 and an age at onset of 33. For comparison, we also
chose four individuals with equivalent CAG repeats but a
more typical age at neurologic onset. None of these four,
GUS21069, GUS2433, GUS20708 and GUS18027, who
had CAG repeats of 45, 46, 46, and 47 units and exhibited
neurologic onset at 58, 57, 50 and 54 years, respectively,
possessed either a 16 or 17 GRIK2 TAA allele (Table 1). To
identify a functional polymorphism associated with the
early onset phenotype, we sequenced the exons and exon
boundaries for GRIK2 in all of these individuals.
GRIK2 comprises 17 exons spanning ~670 kb in 6q16.3,
with alternative splicing capable of producing alternative
carboxyl termini for the protein (Figure 1). Sequencing of
all exons revealed no coding sequence or boundary
changes specific to patients with earlier than expected HD
onset. In the eight HD individuals, we identified polymor-
phisms in the flanking sequences of exons 6 (2 SNPs), 7,
12, and 13, and in the coding sequences of exons 14 and
15, corresponding to known SNPs rs2852565, rs2786251,
rs6922753, rs2518283, rs2243355, rs3213607, and
rs2227283, respectively (Table 2). Neither of the codingBMC Neuroscience 2006, 7:62 http://www.biomedcentral.com/1471-2202/7/62
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sequence variants is predicted to alter an amino acid. The
only other GRIK2  coding sequence SNPs reported in
dbSNP are rs3213608 and rs2235076, which are pre-
dicted to cause V>I and M>I changes in exons 14 and 17,
respectively [17] We did not detect either of these in any
of the 8 individuals tested.
Testing for a common origin of the alleles associated with 
younger onset
In the absence of a coding sequence variant, we next tested
whether the 16 TAA allele might be in linkage disequilib-
rium with a functional variant in noncoding sequence or
in an adjacent gene. This would predict that the particular
chromosomes associated with the early onset phenotype
would share a common ancestral origin. Consequently,
we typed 8 microsatellite markers across the GRIK2 locus.
These locations are shown in Figure 1, with the genotypes
for the individuals tested in Table 2. Markers upstream
from GRIK2 and in introns 3, 11 and 13 gave no evidence
for a common haplotype shared among the individuals
with a 16 TAA allele. Indeed, for the markers in introns 11
and 13, nearest the 3'UTR, at best two of the 3 individuals
(GUS3223 and GUS17508) could have shared a two
marker haplotype, '160' at D6S1709 (AFMA070ZD9) and
'216' at GATA164H01. However, genotyping of the
mother and a sibling of GUS3225 revealed that the 16
TAA allele was in coupling with the alternate
GATA164H01 allele, 220 (data not shown). These data
suggest that if the chromosomes bearing a 16 TAA allele
and capable of modifying onset age share a common ori-
gin, the shared ancestral region would be 3' to the markers
in intron 13. Combining these data with the SNP geno-
types described above suggests further that a segment
shared by the 16 allele chromosomes would be 3' to the
missense SNP in exon 14, as GUS3225 and GUS17507
differ at this site on the 16 TAA allele chromosome.
The 2 Mb genomic region downstream from GRIK2 shows
no known genes in the March 2006 (hg18) assembly of
the human genome sequence [18]. We tested the nearest
polymorphic microsatellites, ~1 Mb from the GRIK2
3'UTR. The presence of a 149 allele for D6S1580
(AFM183YH4) in GUS3225, GUS17507, and GUS17508
left open the possibility of a common origin for this ~1
Mb segment. To narrow this possibility to GRIK2 itself, we
next sequenced the GRIK2 3'UTR region and the 3' por-
tion of intron 16 in the same eight individuals, seeking
additional polymorphisms that would help to delineate a
potential common ancestral origin for the 3' end of the
gene. Upstream from exon 17, we detected three known
SNPs: rs2852620, rs1034254, and rs12198351. Though
Paschen et al. provided evidence that the TAA repeat is
present in the 3'UTR, the full extent of the latter has not
been well characterized and is not completely represented
in current genome database annotations [19]. Conse-
quently, we examined a segment of ~2 kb downstream
from the TAA termination codon of GRIK2. We chose this
segment based on sequence similarity with GRIK2 ortho-
logues from Xenopus, chicken, mouse, rat, dog and chimp
(Figure 2) and its presence in mouse and rat Grik2
mRNAs. We found two novel SNPs, T>C at 248 bp and
T>C at 617 bp 3' to the TAA repeat, which have been des-
ignated rs28383483 and rs28383484, respectively (Figure
1).
To simplify haplotype determination across the GRIK2
gene, we segregated the individual chromosome 6s from
GUS3225 and GUS17508 in hybrid cell lines. As no lym-
phoblast cell line was available for GUS17507, we also
relied on genotyping two siblings of this individual in an
attempt to limit possible haplotypes. We typed these
hybrid lines and GUS17507 relatives for the TAA repeat
and the two new 3'UTR polymorphisms, and we retyped
Table 1: Selected HD patients with similar CAG repeat size but different onset ages
Patient HD CAG Repeat Age of onset (yrs) GRIK2 TAA repeat
HD allele/normal allele allele 1/allele2
Early onset
GUS3225 46/18 28 14/16
GUS17507 45/26 33 15/16
GUS17508 47/16 29 13/16
GUS17843 46/23 33 14/17
Typical onset
GUS2433 46/19 57 14/14
GUS18027 47/21 54 14/15
GUS20708 46/17 50 12/15
GUS21069 45/17 58 15/15BMC Neuroscience 2006, 7:62 http://www.biomedcentral.com/1471-2202/7/62
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selected polymorphisms reported above to directly con-
firm local haplotypes.
The haplotypes associated with the three 16 TAA alleles
and one 17 TAA repeat allele from the individuals with
earlier than expected onset of HD are shown in Figure 3.
Phasing of the alleles for the previously analyzed poly-
morphisms revealed that, on the chromosome associated
with younger HD onset, all individuals differ for the hap-
lotype of SNPs at exons 14 and 15. This suggests that any
potentially shared region responsible for the modifier
effect would lie 3' to exon 15. Further, GUS3225 and
GUS17507 differ from GUS17508 for the SNPs in intron
16, suggesting that any ancestrally shared region would lie
Genomic structure of GRIK2 and locations of microsatellites and SNPs Figure 1
Genomic structure of GRIK2 and locations of microsatellites and SNPs. The relative positions of nine microsatellites 
chosen using the Human Genome Database and the UCSC Genome Browser are shown above a bar, oriented from centro-
mere (cen) to telomere (tel), representing the chromosome 6q16.3 region containing GRIK2 [18, 33]. The GRIK2 gene, com-
prising 17 exons (numbered) is expanded below the bar, and the region from exon 11 through the 3'UTR is further expanded 
below. The annotation of the 3'UTR region of GRIK2 in human genome databases is incomplete, indicating only a shorter tran-
script associated with use of a polyadenylation signal upstream from the TAA repeat. Data from [29] indicate that two polya-
denyation signals may be used, producing either a shorter mRNA, without the TAA repeat, or a longer mRNA that contains it. 
Coding sequences are shown in dark blue and UTRs are shown in light blue, with introns shown as a thin black bar. The loca-
tions of relevant microsatellites and SNPs are denoted by downward and upward-pointing triangles, respectively. SNPs located 
in the GRIK2 gene are denoted by letter: a: rs2852565, b: rs2786251, c: rs6922753, d: rs2518283, e: rs2243355, f: rs3213607, g: 
rs2227283, h: rs2852620, i: rs1034254, j: rs12198351, k: rs28383483, l: rs28383484. The last polymorphism is located at the 
edge of the region of extended homology with rodent mRNAs (see Figure 2) and may lie either at the extreme end of the 
human 3'UTR or immediately outside of it.
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3' to rs12198351, 1.7 kb upstream from the TAA repeat.
However, GUS3225 differs on the 16 TAA chromosome
from the other individuals at SNP rs28383484, suggesting
that any ancestrally shared region would lie 5' to this site,
617 bp downstream of the TAA repeat. Within the seg-
ment between SNPs rs12198351 and rs28383484, which
we sequenced in its entirety, only the TAA repeat allele
consistently distinguishes these chromosomes from chro-
mosomes not associated with younger than expected
onset of HD, suggesting that the length of the TAA allele
itself is responsible for the modifier effect.
Discussion
GRIK2, encoding the GluR6 subunit of the kainate recep-
tor, is abundantly expressed in the caudate nucleus, cor-
tex, hippocampus and cerebellum in human. Kainate
receptors are one of three subtypes of ionotropic receptors
for the excitatory amino acid transmitter L-glutamate.
They both mediate excitatory synaptic transmission at pri-
mary afferent synapses and modulate presynaptic neuro-
transmitter release [20]. Interaction of excitatory amino
acids with their receptors can potentially cause toxicity
that upsets Ca++ homeostasis and damages energy metab-
olism, and such 'excitotoxicity' due to glutamate has long
been postulated to be involved in HD pathogenesis
[21,22]. However, a recent analysis of systemic 3-nitro-
propionic acid induced striatal lesions in Grik2-/- mice
showed no difference in final histopathology or motor
impairment compared with similarly treated wild-type
mice, suggesting that striatal GluR6 kainate receptors do
not play a critical role in determining neuronal pathology
[23]. In this experiment, Grik2-/- mice did display motor
symptoms earlier than wild-type mice, despite the lack of
difference in neuropathology, suggesting that the GluR6
kainate receptors may have played some modulatory role
in synaptic transmission rather than mediating excitotox-
icity.
There is abundant evidence that genetic modifiers of HD
pathogenesis exist, from studies performed before the HD
gene was cloned through studies performed more recently
with the benefit of molecular definition of the HD muta-
tion [5-16,24,25]. GRIK2  is currently the only genetic
modifier of HD that has been specifically identified and
confirmed in more than two independent studies [6,7,11-
13]. Our findings indicate that 'modifier' chromosomes
did not have a functional coding sequence difference that
directly alters GluR6. Rather, they shared the 16 TAA allele
but had different haplotypes for SNPs within a 2.3 kb
region encompassing the polymorphic repeat, suggesting
that the TAA allele itself, rather than a linked polymor-
phism, is responsible for the modifier effect. Though the
effect may be peculiar to 16 TAA alleles, we cannot
exclude that it is a length-dependent effect encompassing
both 16 TAA and longer alleles, as there are too few 17
TAA alleles to test for a statistically significant modifier
Table 2: Genotypes in the GRIK2 region in selected HD patients
Earlier Age of Onset Normal Age of Onset
GUS3225 GUS17507 GUS17508 GUS17843 GUS2433 GUS18027 GUS20708 GUS21069
SNPs
rs2786251 (Intron 5) G/G G/G G/G G/G G/G G/G A/A G/G
rs6922753 (Intron 5) C/C C/C C/C C/C C/C C/C G/G C/C
rs6922753 (Intron 7) T/T T/C T/T T/T T/C T/T T/C T/T
rs2518283 (Intron 11) T/T T/T T/T T/T T/T T/T T/C T/T
rs2243355 (Intron 12) G/A G/G G/G A/A G/A G/A G/G G/G
rs3213607 (Exon 14) A/A C/C C/A C/C C/C C/A C/C C/A
rs2227283 (Exon 15) G/A A/A G/A G/G G/A G/G G/G G/A
rs2852620 (Intron 16) A/T A/A A/T T/T A/T T/T T/T A/T
rs1034254 (Intron 16) T/C T/T T/C C/C T/C C/C C/C T/C
rs12198351 (Intron 16) C/C G/G C/C C/C G/C C/C C/C C/C
rs28383483 (3'UTR) T/T T/T T/C T/T T/T T/T T/T T/T
rs28383484 (3'UTR) T/C T/T T/T T/T T/T T/T T/T C/C
Microsatellites
D6S468 152/154 154/156 152/156 150/158 156/160 156/158 154/156 152/158
D6S1555 290/294 296/296 294/294 290/292 294/296 290/296 294/296 290/296
D6S449 197/197 197/197 197/197 195/197 197/197 197/197 191/191 No data
D6S1709 153/160 149/149 149/160 153/153 149/153 153/153 153/168 149/160
GATA164H01 216/220 224/224 216/232 212/232 224/224 220/224 220/232 220/224
D6S1028 (TAA) 14/16 15/16 13/16 14/17 14/14 14/15 12/15 15/15
D6S1580 149/149 149/168 149/160 149/157 160/162 149/168 149/153 149/162
D6S1679 253/253 249/253 243/244 244/253 242/244 242/242 243/247 244/244
D6S301 228/228 228/228 246/248 228/248 242/248 244/244 236/246 248/248BMC Neuroscience 2006, 7:62 http://www.biomedcentral.com/1471-2202/7/62
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effect. However, the very early onset of GUS17843 sug-
gests that 17 TAA alleles may also have the potential to
modify neurologic onset in HD.
It is likely that the 3' UTR TAA repeat modifier effect acts
at the level of the GRIK2 mRNA, with multiple opportuni-
ties for allelic alterations in regulation beyond considera-
tions of translational efficiency and stability. Indeed, with
the exception of the immediate vicinity of the TAA repeat,
the 3'UTR of GRIK2 is remarkably conserved across spe-
cies, suggesting that it has an important regulatory role
(Figure 2). GRIK2 displays alternative splicing of exon 16
that leads to two major splice variants encoding proteins
with different carboxyl-termini. Two other minor alterna-
tive splice forms, one skipping exon 12 (predicting a trun-
cated protein) and one in which a cryptic splice site in
exon 11 joins to exon 13 (predicting a protein lacking the
first two of four transmembrane domains), have been
described. Moreover, three major A to I RNA editing sites
that can affect ion permeability of the receptor due to
Evolutionary conservation of the GRIK2 3'UTR region Figure 2
Evolutionary conservation of the GRIK2 3'UTR region. Plots comparing chimpanzee, dog, rat, mouse, chicken and frog 
orthologue sequences to the conserved 3'UTR region of human GRIK2 were generated using mVISTA [34-36]. For the human 
sequence, we chose chr6: 102623080–102624690, comprising 1610 bp sequence downstream from the stop codon, based 
upon the report of a polyadenylation signal at 1547 bp after the stop codon [29]. The relative location of the polymorphic TAA 
repeat within the human sequence is shown between vertical lines (from 787 to 828bp). Plots show % identity over a 100 bp 
window (vertical axis) of chimpanzee (chr5 (Nov 2003): 104613747-104615339), dog (chr12 (July 2004): 62913564-62915139), 
rat (chr20 (June 2003): 53258651-53260220), mouse (chr10 (May 2004): 49099305-49100874), chicken (chr3 (Feb 2004): 
68531473-68532948), and frog (Xenopus tropicalis) (Scaffold-599 (Oct 2004): 27668-29079), respectively, relative to the human 
sequence (horizontal axis) [18].
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resulting amino acid substitutions I>V, Y>C and Q>R,
respectively are located in exons 11 (2) and 12. Fully
unedited receptors at the Q/R site exhibit higher relative
calcium permeability and higher channel conductance as
compared to edited receptors [26-28]. Interestingly, two
alternative transcripts differing in the length of the 3'UTR
have been reported, only one of which includes the TAA
repeat [19,29]. The shorter mRNA uses a polyadenylation
signal located 92 bases after the stop codon, upstream of
the TAA repeat while the longer mRNA extends beyond a
putative polyadenylation signal 1547 bases downstream
of the stop codon, 3' to the TAA repeat [29]. Thus, numer-
ous opportunities exist for the TAA repeat polymorphism
to potentially modify HD onset by virtue of an allelic reg-
ulatory effect on the production, polyadenylation status,
alternative splicing, subcellular targeting, editing or stabil-
ity of the GRIK2  mRNA. The aforementioned Grik2-/-
mouse experiments also indicate that an effect on age at
neurologic onset may not necessarily be mediated by exci-
totoxicity, but could occur due to an independent effect
on motor function. The fact that GRIK2 is capable of mod-
ifying the pathogenic process in HD sufficiently to have a
noticeable impact on onset age indicates that it is a poten-
tial target for development of an effective therapeutic
intervention. However, it will be necessary to delineate of
the precise basis for the GRIK2 modifier effect in order to
effectively undertake a search for chemical compounds
that delay, rather than hasten HD onset.
Conclusion
GRIK2 acts as a modifier of HD pathogenesis, not through
a coding sequence polymorphism that changes the struc-
ture of the GluR6 protein, but rather through a TAA repeat
polymorphism in the 3'UTR. Translating this knowledge
into a treatment to delay HD pathogenesis will first
require definition of the functional consequences of the
TAA repeat, possibly involving altered regulation of
GRIK2 mRNA.
Methods
Patient DNA and cell lines
After informed consent was obtained in accord with insti-
tutional review board (IRB) policies, blood samples were
obtained from patients and family members. Standard
methods were used for extraction of DNA and, in some
cases, generation of lymphoblastoid cell lines.
Statistical analysis
Variability in onset age attributable to the CAG repeat
number was controlled by linear regression using the log-
arithmic transformed age at onset as the dependent varia-
ble and GRIK2 TAA, normal CAG repeat, HD CAG repeat,
GRIK2 3' haplotypes in HD patients with earlier than expected onset Figure 3
GRIK2 3' haplotypes in HD patients with earlier than expected onset. Haplotypes determined for microsatellite and 
SNP (labeled as in Figure 1) markers from GRIK2 exon 11 through the 3'UTR are shown for the four HD patients with earlier 
than expected onset, three possessing a 16 TAA allele at D6S1028 and one possessing a rare 17 TAA allele. The 16 TAA allele 
chromosomes are distinguishable by other polymorphisms except in the fully sequenced 2.3 kb region between rs12198351 
and rs28383484 (denoted by a red bar above this region of the haplotype) suggesting that the TAA allele is responsible for the 
modifier effect.
Intron11   Intron12 Intron13 Exon14 Exon15    Intron16 3'UTR
__________  ________ ________ ______ ______  ________________  __________________
D6S1709 d      e GATA164H01 f      g      h     I  j      TAA     k       l
GUS3225
haplotype 1 153      T      G      220      A      A      A      T      T 16      T C
haplotype 2 160      T      A      216    A      G      T      C      T 14      T      T
GUS17507
haplotype 1 149      T      G      224      C      A      A      T      T 16      T T
haplotype 2 149      T      G      224    C      A      A      T      T 15      T      T
GUS17508
haplotype 1 149      T      G      216      A      G      T      C      C 16      T T
haplotype 2 160      T      G      232    C      A      A      T      T 13      C      T
GUS17843
haplotype 1 153      T      A      212    C      G      T      C      T 17      T      T
haplotype 2 153      T      A      232    C      G      T      C      T 14      T      TBMC Neuroscience 2006, 7:62 http://www.biomedcentral.com/1471-2202/7/62
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and the product term between normal CAG repeat and
HD CAG repeat as independent variables [30-32].
GRIK2 sequencing
We amplified 17 coding exons of GRIK2 (NM_021956)
and 1991 base pairs downstream from the stop codon,
with primers located in flanking intron and UTR
sequences. Amplification was performed in a standard 30
μl PCR reaction (in 10 mM Tris, pH 8.9, 50 mM KCl, 1.5–
2.5 mM MgCl2, 10 pmol of each primer and 200 μM of
each dNTP, including 50–100 ng DNA and 1U Taq
polymerase (Invitrogen) using an MJ Research PT-100
with the following conditions: 94°C, 4 min, 30 X (94°C,
45s; 50–60°C, 45s; 72°C, 1 min), 72°C, 10 min. PCR
products were analyzed by direct sequencing by using
BigDye Terminator Cycle Sequencing Kit (Applied Biosys-
tems) on an ABI 377/XL DNA Sequencer (Perkin-Elmer).
Microsatellite genotyping
PCR used 30 ng/ul genomic DNA; 0.1–1.0 ul (4 uM Stock
Markers) of each dye-labeled primer pair (Research Genet-
ics and custom oligos from Applied Biosystems); 0.1 ul (5
units/ul) Ampli Taq Gold DNA polymerase (Applied Bio-
systems); 0.75 ul10x GeneAmp PCR buffer II (Applied
Biosystems); 0.75 ul dNTP mix (2.5 mM, Amersham);
0.75 MgCl2 (25 mM); and dH20 to 7.5 ul, and was exe-
cuted in the MJ Research DNA Engine tetrad with the fol-
lowing conditions: 95°C, 12 min;10X (94°C, 30s, 58°C,
30s; 72°C, 60s); 25X (89°C, 30s; 55°C, 30s; 72°C, 60s);
72°C, 40 min. Except for D6S1555, D6S1028, D6S449,
D6S1580 which cycled: 95°C, 5 min; 35X (94°C, 30s;
50°C, 30s; 72°C, 45s) 72°C, 10 min. D6S301  cycled:
95°C, 5 min; 53X (94°C, 30s; 54°C, 30s; 72°C, 45s)
72°C, 10 min. PCR products were run on a 5%
Gene_PAGE PLUS (Amresco) gel on an ABI 377/XL DNA
Sequencer for three hours, with a size standard GeneScan-
500 TAMRA) in each lane to ensure lane-to-lane and gel-
to-gel size-calling consistency. Data were analyzed with
ABI's GeneScan Version 3.1 and Genotyper version 2.5
software.
Abbreviations
HD, Huntington's disease; UTR, untranslated region.
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